Cargando…
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
BACKGROUND: Ovarian cancer is the fifth leading cause of cancer death in women in the US. With poly(ADP-ribose) polymerase (PARP) inhibitors having shown promising results in ongoing trials, there is interest in better understanding their economic value. OBJECTIVE: This study aimed to review and eva...
Autores principales: | Gao, Wei, Muston, Dominic, Monberg, Matthew, McLaurin, Kimmie, Hettle, Robert, Szamreta, Elizabeth, Swallow, Elyse, Zhang, Su, Kalemaj, Iden, Signorovitch, James, McQueen, R. Brett |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547040/ https://www.ncbi.nlm.nih.gov/pubmed/32794041 http://dx.doi.org/10.1007/s40273-020-00949-9 |
Ejemplares similares
-
Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data
por: Arend, Rebecca C., et al.
Publicado: (2021) -
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
por: Fan, Lin, et al.
Publicado: (2022) -
RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015) -
Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019) -
The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)